C12N2502/1323

Biocompatible conditioned cell medium compositions and uses thereof
11987806 · 2024-05-21 · ·

The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and/or gum tissue growth.

Method of manufacturing cell spheroid using bioink

Disclosed is a process of manufacturing cell spheroids using a bioink. More particularly, provided is a method of manufacturing a cell spheroid, the method including extruding a first bioink including an alginate; extruding a second bioink including cells into the extruded first bioink; adding a calcium chloride (CaCl2) solution to the alginate included in the first bioink; and dissolving the second bioink, present in the first bioink, in a cell culture medium to form a cell spheroid from the cells.

STROMA-FREE NK CELL DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS

The technology described herein is directed to stromal-free methods of NK cell differentiation. Also described herein are cells differentiated using stromal-free methods and compositions comprising such cells. In some embodiments, the cells can be genetically modified. In some embodiments, the cells or compositions comprising said cells can be administered to a patient to treat cancer or as a cellular replacement therapy to treat a condition.

Methods relating to intestinal organ-on-a-chip

Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.

Preparation of artificial tissues by means of tissue engineering using fibrin and agarose biomaterials

The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ.

Immortalization of Epithelial Cells and Methods of Use
20190233798 · 2019-08-01 ·

The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.

GENERATION OF CANCER STEM CELLS AND USE THEREOF
20190194622 · 2019-06-27 ·

Methods, kits and compositions for generating cancer stem cells are provided.

Method for preparing a three-dimensionally cultured skin comprising dermis and epidermis, and the cultured skin made therefrom
10323230 · 2019-06-18 · ·

The present invention includes a method for preparing a three-dimensionally cultured skin model comprising dermis and epidermis, which comprises: a step of preparing the dermis using a composition comprising murine fibroblasts; and a combination of native collagen and atelocollagen; and a step of forming the epidermis using keratinocytes. Also, the present invention relates to a three-dimensionally cultured skin model which comprises: a dermis prepared by a composition comprising murine fibroblasts, native collagen, or a combination of native collagen and atelocollagen; and epidermis formed from keratinocytes.

PREPARATION AND APPLICATIONS OF RGD CONJUGATED POLYSACCHARIDE BIOINKS WITH OR WITHOUT FIBRIN FOR 3D BIOPRINTING OF HUMAN SKIN WITH NOVEL PRINTING HEAD FOR USE AS MODEL FOR TESTING COSMETICS AND FOR TRANSPLANTATION
20190160203 · 2019-05-30 ·

The present invention relates to use of hydrogel based on RGD-conjugated alginate with and without addition of nanocellulose and/or fibrin as a novel bioink for 3D Bioprinting of human skin, particularly dermis. RGD-conjugated alginate provides adhesion sites for the human fibroblasts which result in cell adhesion and stretching which contribute to upregulation of genes producing Collagen I. In this invention, RGD-conjugated alginate is used as one of the components of the bioink for 3D bioprinting. Another innovation described herewith is use of coaxial needle when 3D bioprinting with alginate and RGD-modified alginate bioinks. A coaxial needle makes it possible to crosslink the bioink upon 3D bioprinting operation and thus achieve high printing fidelity which is required for high cell viability, proliferation and production of extracellular matrix. In this invention, the novel RGD-modified alginate bioink together with human fibroblasts is 3D bioprinted and the resulting construct shows high cell viability, high cell proliferation, high degree of stretching of fibroblasts and high productivity of Collagen I. The cell bioink construct biofabricated with this invention is ideal for testing cosmetics and active ingredients of skin care products particularly those used for skin regeneration. It is also ideal to be used as skin grafts for skin repair for patients with damaged or burned skin.

HUMAN PLURIPOTENT STEM CELL-DERIVED SECRETOME AS A BIOLOGIC FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE AND APOPTOTIC DISEASES

In various embodiments, neuroprotective compositions and uses thereof are provided. In certain embodiments, a method of protecting mammalian neurons from neurotoxins, oxidative stress or protein aggregation, mitochondrial dysfunction, inflammatory gene expression, induced cell death is provided where the method involves contacting the cells, such as neurons, with an effective amount of: a plurality of proteins that are secreted by induced pluripotent stem cells (iPSCs) derived from a healthy mammal and/or from a mammal with a disease, such as neurodegenerative pathology, exemplified by amyotrophic lateral sclerosis (ALS) where said proteins are secreted when said iPSC cells are pluripotent; and/or biologically active fragments of said proteins; and/or biologically active analogs of said proteins.